Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035321 · ClinicalTrials.gov registry record · Phase 3
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00035321 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 600 participants.
The verdict
NCT00035321, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purposes of this study are to determine: * Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression. * The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination. * The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone.
Interventions
- DRUG Olanzapine
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2002-04 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035321
The ClinicalTrials.gov registry entry for NCT00035321 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT00035321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035321 about?
NCT00035321 is a clinical study titled "The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression". The purposes of this study are to determine: * Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression. * The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination. * The ef...
What is the current status of trial NCT00035321?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2002-04. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00035321?
The interventions under investigation include: Olanzapine (DRUG), Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00035321?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.